Caplin Point Laboratories Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 1810 as of 12 May 15:30 . The P/E Ratio of Caplin Point Laboratories Ltd changed from 12.6 on March 2021 to 28.4 on March 2025 . This represents a CAGR of 17.65% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3057 crore on March 2021 to ₹ 15222 crore on March 2025 . This represents a CAGR of 37.86% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 576.45 crore as compare to the Sep '25 revenue of ₹ 564.43 crore. This represent the growth of 2.13% The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The ebitda of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 223.35 crore as compare to the Sep '25 ebitda of ₹ 219.56 crore. This represent the growth of 1.73% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The net profit of Caplin Point Laboratories Ltd changed from ₹ 124.92 crore to ₹ 165.86 crore over 7 quarters. This represents a CAGR of 17.58% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The Dividend Payout of Caplin Point Laboratories Ltd changed from 14.53 % on March 2021 to 13.43 % on March 2025 . This represents a CAGR of -1.56% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Caplin Point Laboratories Ltd

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990.
The Company is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.
Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries.
In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Caplin Point Laboratories Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Caplin Point Laboratories Ltd or Morepen Laboratories Ltd?

Market cap of Caplin Point Laboratories Ltd is 14,088 Cr while Market cap of Morepen Laboratories Ltd is 2,505 Cr

What are the key factors driving the stock performance of Caplin Point Laboratories Ltd and Morepen Laboratories Ltd?

The stock performance of Caplin Point Laboratories Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Caplin Point Laboratories Ltd and Morepen Laboratories Ltd?

As of May 12, 2026, the Caplin Point Laboratories Ltd stock price is INR ₹1853.5. On the other hand, Morepen Laboratories Ltd stock price is INR ₹45.73.

How do dividend payouts of Caplin Point Laboratories Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Caplin Point Laboratories Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.